financetom
Business
financetom
/
Business
/
Upstart Holdings Soars 17% After Analyst Update : What You Need To Know
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Upstart Holdings Soars 17% After Analyst Update : What You Need To Know
Oct 17, 2024 12:22 PM

Upstart Holdings, Inc. ( UPST ) shares are trading higher Monday following an upgrade by Wedbush analyst David Chiaverini. The firm raised its rating from Underperform to Neutral, while significantly increasing its price target from $10 to $45.

What To Know: Chiaverini highlighted that Upstart’s ability to diversify its funding base through long-term capital providers, along with stronger credit buyer demand, is positioning the company for a potential rebound. The analyst noted that recent Asset Backed Securities deals have shown better-than-expected delinquency performance, marking a positive shift for the company after several challenging quarters. However, he cautioned that while recent improvements are encouraging, the company's ability to scale originations while maintaining credit performance remains a key question moving forward.

Analyst Opinions: Analysts have given mixed ratings for Upstart Holdings ( UPST ), with a current average 12-month price target of $32.22, up 53.43% from the previous $21.00. Key upgrades include Wedbush raising its target to $45.00 and Mizuho to $48.00.

What Else: Upstart's market capitalization now stands at approximately $4.16 billion, with shares trading near the upper end of their 52-week range, reflecting the renewed confidence in its long-term growth trajectory.

UPST Price Action: Upstart Holdings ( UPST ) shares were up by 17.3% at $55.16 at the time of writing, according to Benzinga Pro.

See Also:

High Expenses to Hurt Fifth Third’s Q3 Earnings, Fee Income to Ail

Image: courtesy of Upstart Holdings Inc. ( UPST )

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--L3Harris Technologies Lifts Full-Year 2024 Adjusted Segment Operating Margin Guidance to 15.5%
--L3Harris Technologies Lifts Full-Year 2024 Adjusted Segment Operating Margin Guidance to 15.5%
Oct 25, 2024
04:44 PM EDT, 10/24/2024 (MT Newswires) -- Price: 254.00, Change: +9.83, Percent Change: +4.03 ...
Deckers Outdoors raises annual sales forecast on strong demand for Hoka shoes
Deckers Outdoors raises annual sales forecast on strong demand for Hoka shoes
Oct 25, 2024
Oct 24 (Reuters) - Deckers Outdoor ( DECK ) beat Wall Street estimates for second-quarter results and raised its annual sales forecast on Thursday, as its brands such as UGG boots and Hoka running shoes continue to resonate with customers. The company's shares were up 8.5% at $164.80 after the bell, set to add to the about 35% gain so...
US court blocks Tapestry's $8.5 billion acquisition of rival Capri
US court blocks Tapestry's $8.5 billion acquisition of rival Capri
Oct 25, 2024
NEW YORK, Oct 24 (Reuters) - A U.S. judge blocked the pending $8.5 billion merger of U.S. handbag and accessories maker Tapestry and Capri on Thursday, a victory for the U.S. Federal Trade Commission in an industry where merger challenges are rare. The FTC argued at an eight-day trial in New York that the merger would eliminate fierce head-to-head competition...
Marinus Pharmaceuticals Shares Plunge as Phase 3 Trial of Ganaxolone Fails to Meet Goal; Plans to Cut Costs, Explore Alternatives
Marinus Pharmaceuticals Shares Plunge as Phase 3 Trial of Ganaxolone Fails to Meet Goal; Plans to Cut Costs, Explore Alternatives
Oct 25, 2024
03:08 PM EDT, 10/24/2024 (MT Newswires) -- Marinus Pharmaceuticals ( MRNS ) shares plunged nearly 82% in recent Thursday trading after the company said its phase 3 trial of oral ganaxolone failed to meet its main goal and announced plans to reduce costs and explore alternatives for the business. Marinus was studying the drug as a treatment for seizures associated...
Copyright 2023-2025 - www.financetom.com All Rights Reserved